Ilyang Pharmaceutical Co.,Ltd (KRX:007570)

South Korea flag South Korea · Delayed Price · Currency is KRW
8,160.00
-280.00 (-3.32%)
Last updated: Jul 14, 2026, 2:42 PM KST
Market Cap147.52B -26.6%
Revenue (ttm)275.51B +1.3%
Net Income19.54B +88.2%
EPS1,116.30 +94.7%
Shares Out 17.92M
PE Ratio7.37
Forward PEn/a
Dividend155.00 (1.84%)
Ex-Dividend DateDec 29, 2025
Volume27,884
Open8,580.00
Previous Close8,440.00
Day's Range8,100.00 - 8,580.00
52-Week Range7,290.00 - 16,240.00
Beta0.43
Analystsn/a
Price Targetn/a
Earnings DateAug 13, 2026

About KRX:007570

Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, antifungal drugs, anti-inflammatory analgesic drugs, insecticides, and vaccines; and health drinks, daily food, supplements, health food, cosmetics, and be... [Read more]

Sector Healthcare
Founded 1946
Employees 666
Stock Exchange Korea Stock Exchange
Ticker Symbol 007570
Full Company Profile

Financial Performance

In 2025, KRX:007570's revenue was 272.42 billion, an increase of 1.39% compared to the previous year's 268.68 billion. Earnings were 6.73 billion, a decrease of -25.52%.

Financial Statements